A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
This clinical trial is studying advanced or metastatic solid tumors. Once a solid tumor
has grown very large in one spot or has spread to other places in the body, it is called
advanced or metastatic cancer. Participants in this study must have head and neck
squamous...
Age: 18 years - 66+
Gender: All
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
This phase I/Ib trial is to find out the best dose, possible benefits and/or side effects
of BET bromodomain inhibitor ZEN-3694 (ZEN003694) when given in combination with
nivolumab with or without ipilimumab in treating patients with solid tumors. ZEN003694
may stop ...
Age: 18 years - 66+
Gender: All
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study
of BT8009 given as a single agent and in combination with pembrolizumab in participants
with advanced solid tumors associated with Nectin-4 expression or in participants with
ad...
Age: 18 years - 66+
Gender: All
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with
atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian tube, or
primary peritoneal cancer that has come back (recurrent). Chemotherapy drugs, such ...
Age: 18 years - 66+
Gender: Female